Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease

L. M. Bekris, M. Khrestian, E. Dyne, Y. Shao, J. Pillai, S. Rao, S. M. Bemiller, B. Lamb, H. H. Fernandez, J. B. Leverenz

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Alzheimer's disease (AD) has been genetically and pathologically associated with neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor involved in innate immunity. TREM2 rare protein coding genetic variants have been linked to AD. A soluble TREM2 (sTREM2) cleavage product is elevated in AD. It is unclear whether there is a relationship between elevated sTREM2 and markers of inflammation. The hypothesis of this investigation was that central and peripheral inflammation play a role in sTREM2 levels in AD. A consistent association of peripheral or central markers of inflammation and CSF sTREM2 levels was not found, suggesting a limited impact of general inflammation on sTREM2 levels. An association between peripheral sTREM2 levels and CSF sTREM2, as well as an association between CSF sTREM2 and a marker of blood brain barrier integrity, was observed in AD, suggesting a potential role of peripheral TREM2 in central TREM2 biology.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalJournal of Neuroimmunology
Volume319
DOIs
StatePublished - Jun 15 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease'. Together they form a unique fingerprint.

  • Cite this

    Bekris, L. M., Khrestian, M., Dyne, E., Shao, Y., Pillai, J., Rao, S., Bemiller, S. M., Lamb, B., Fernandez, H. H., & Leverenz, J. B. (2018). Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. Journal of Neuroimmunology, 319, 19-27. https://doi.org/10.1016/j.jneuroim.2018.03.003